Delhi hospitals face risks as questionable medicines raise concerns, with investigations and strict actions underway.
NEW DELHI: There is bad news for patients receiving treatment in Delhi government hospitals—if the hospital administration shows even a little negligence, thousands of patients could lose their lives.
We are not saying that patients are being given fake or substandard medicines during treatment here. However, The Sunday Guardian has documents proving that, on behalf of the Directorate General of Health Services (DGHS) of the Delhi government, a complaint was made about Iron/Ferric Carboxy Maltose 500mg/10ml injection from BDR Pharmaceutical International Private Limited used in Guru Govind Singh Government Hospital (GGSGH) and Dr Hedgewar Aarogya Sansthan (DHAS). Some batches of this medicine reportedly caused allergic reactions and adverse drug reactions (ADR). Additionally, a fungal ball was observed in Ringer Lactate Pack Injection 500ml of Swaroop Pharmaceutical Private Limited /Sanyog Life Care at Govind Ballabh Pant Hospital. After receiving complaints about these medicines, DGHS sent special samples to an NABL-accredited lab for testing.
Meanwhile, hospital administrations have been ordered to be cautious regarding these medicines or ban their use until the investigation report is released, or further
orders are given, as of June 27, 2025.
Apart from this, Delhi’s Health Minister Dr Pankaj Singh made a significant statement
about the quality of cancer medicines last week, saying that 100 cancer medicine samples were collected from the market and sent for investigation. He added that strict action would be taken if anyone is found guilty.
In this situation, it will be interesting to see whether any action is taken against the companies supplying such medicines to Delhi government hospitals.
